Prime Medicine, Inc. Operating Income
Prime Medicine, Inc. (PRME) reported Operating Income of -$43.28 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-06
- Prime Medicine, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$43.28M.
- Prime Medicine, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$50.65M.
- Prime Medicine, Inc. operating income (loss) for the quarter ending 2025-12-31 was -$48.61M.
- Prime Medicine, Inc. operating income (loss) for the quarter ending 2025-09-30 was -$53.97M.
- Prime Medicine, Inc. operating income (loss) for fiscal 2025 was -$208.35M.
- Prime Medicine, Inc. operating income (loss) for fiscal 2024 was -$202.47M.
- Prime Medicine, Inc. operating income (loss) for fiscal 2023 was -$204.79M.
- Prime Medicine, Inc. operating income (loss) for fiscal 2022 was -$116.54M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$43.28M 10-Q · filed 2026-08-06 | -$93.94M 10-Q · filed 2026-08-06 | -$142.55M derived: sum of 3 quarters · filed 2026-08-06 | -$196.52M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$50.65M 10-Q · filed 2026-05-07 | -$99.26M derived: sum of 2 quarters · filed 2026-05-07 | -$153.24M derived: sum of 3 quarters · filed 2026-05-07 | -$206.61M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$48.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$102.58M derived: sum of 2 quarters · filed 2026-03-03 | -$155.96M derived: sum of 3 quarters · filed 2026-08-06 | -$208.35M 10-K · filed 2026-03-03 |
| 2025-09-30 | -$53.97M 10-Q · filed 2025-11-07 | -$107.35M derived: sum of 2 quarters · filed 2026-08-06 | -$159.74M 10-Q · filed 2025-11-07 | -$203.96M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$53.38M 10-Q · filed 2026-08-06 | -$105.77M 10-Q · filed 2026-08-06 | -$149.99M derived: sum of 3 quarters · filed 2026-08-06 | -$204.22M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$52.39M 10-Q · filed 2026-05-07 | -$96.61M derived: sum of 2 quarters · filed 2026-05-07 | -$150.85M derived: sum of 3 quarters · filed 2026-05-07 | -$206.52M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$44.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$98.45M derived: sum of 2 quarters · filed 2026-03-03 | -$154.13M derived: sum of 3 quarters · filed 2026-03-03 | -$202.47M 10-K · filed 2026-03-03 |
| 2024-09-30 | -$54.23M 10-Q · filed 2025-11-07 | -$109.90M derived: sum of 2 quarters · filed 2025-11-07 | -$158.25M 10-Q · filed 2025-11-07 | -$226.29M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | -$55.67M 10-Q · filed 2025-08-07 | -$104.01M 10-Q · filed 2025-08-07 | -$172.06M derived: sum of 3 quarters · filed 2025-08-07 | -$223.51M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$48.34M 10-Q · filed 2025-05-08 | -$116.38M derived: sum of 2 quarters · filed 2025-05-08 | -$167.84M derived: sum of 3 quarters · filed 2025-05-08 | -$213.10M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$68.04M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | -$119.50M derived: sum of 2 quarters · filed 2025-02-28 | -$164.76M derived: sum of 3 quarters · filed 2025-02-28 | -$204.79M 10-K · filed 2025-02-28 |
| 2023-09-30 | -$51.46M 10-Q · filed 2024-11-12 | -$96.72M derived: sum of 2 quarters · filed 2024-11-12 | -$136.75M 10-Q · filed 2024-11-12 | -$175.44M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$45.26M 10-Q · filed 2024-08-08 | -$85.29M 10-Q · filed 2024-08-08 | -$123.98M derived: sum of 3 quarters · filed 2024-08-08 | -$155.63M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$40.03M 10-Q · filed 2024-05-10 | -$78.72M derived: sum of 2 quarters · filed 2024-05-10 | -$110.37M derived: sum of 3 quarters · filed 2024-05-10 | -$136.68M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | -$38.69M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | -$70.34M derived: sum of 2 quarters · filed 2024-03-01 | -$96.65M derived: sum of 3 quarters · filed 2024-03-01 | -$116.54M 10-K · filed 2024-03-01 |
| 2022-09-30 | -$31.66M 10-Q · filed 2023-11-03 | -$57.96M derived: sum of 2 quarters · filed 2023-11-03 | -$77.86M 10-Q · filed 2023-11-03 | -$137.93M derived: sum of 4 quarters · filed 2023-11-03 |
| 2022-06-30 | -$26.30M 10-Q · filed 2023-08-07 | -$46.20M 10-Q · filed 2023-08-07 | -$106.28M derived: sum of 3 quarters · filed 2023-08-07 | -$116.71M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | -$19.90M 10-Q · filed 2023-05-11 | -$79.97M derived: sum of 2 quarters · filed 2023-05-11 | -$90.40M derived: sum of 3 quarters · filed 2023-05-11 | |
| 2021-12-31 | -$60.08M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$70.50M derived: sum of 2 quarters · filed 2023-03-09 | -$84.47M 10-K · filed 2023-03-09 | |
| 2021-09-30 | -$10.43M 10-Q · filed 2022-11-14 | -$24.40M 10-Q · filed 2022-11-14 | ||
| 2020-12-31 | -$932.00K 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |